HC Wainwright set a $5.00 price objective on Alimera Sciences, Inc. (NASDAQ:ALIM) in a research report report published on Friday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.

A number of other equities research analysts have also recently weighed in on ALIM. Rodman & Renshaw started coverage on Alimera Sciences in a research note on Thursday, April 27th. They issued a buy rating and a $4.00 price objective for the company. Zacks Investment Research raised Alimera Sciences from a sell rating to a hold rating in a research note on Tuesday, June 13th. Cowen and Company reaffirmed a buy rating and issued a $3.00 price objective on shares of Alimera Sciences in a research note on Tuesday, July 11th. Finally, ValuEngine raised Alimera Sciences from a sell rating to a hold rating in a research note on Thursday, July 13th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. Alimera Sciences has an average rating of Hold and a consensus target price of $3.38.

Shares of Alimera Sciences (NASDAQ:ALIM) opened at 1.57 on Friday. Alimera Sciences has a one year low of $1.03 and a one year high of $2.40. The firm has a 50 day moving average price of $1.42 and a 200 day moving average price of $1.38. The stock’s market capitalization is $101.89 million.

Alimera Sciences (NASDAQ:ALIM) last issued its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.05) by $0.01. The firm had revenue of $10.40 million during the quarter, compared to analyst estimates of $10.20 million. During the same period in the previous year, the firm posted ($0.17) earnings per share. The company’s quarterly revenue was up 8.3% compared to the same quarter last year. Analysts predict that Alimera Sciences will post ($0.21) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This story was first published by Daily Political and is the property of of Daily Political. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/08/07/hc-wainwright-reiterates-5-00-price-target-for-alimera-sciences-inc-nasdaqalim.html.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ALIM. KCG Holdings Inc. boosted its position in Alimera Sciences by 127.0% in the first quarter. KCG Holdings Inc. now owns 78,604 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 43,977 shares during the last quarter. Kennedy Capital Management Inc. bought a new position in Alimera Sciences during the first quarter valued at approximately $467,000. Finally, JW Asset Management LLC boosted its position in Alimera Sciences by 15.6% in the second quarter. JW Asset Management LLC now owns 966,000 shares of the biopharmaceutical company’s stock valued at $1,343,000 after buying an additional 130,000 shares during the last quarter. 43.58% of the stock is owned by hedge funds and other institutional investors.

Alimera Sciences Company Profile

Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.

Receive News & Ratings for Alimera Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.